Sanofi SA is a French multinational pharmaceutical and healthcare company headquartered in Paris, renowned for its research, development, manufacturing, and marketing of innovative medicines and vacci... Sanofi SA is a French multinational pharmaceutical and healthcare company headquartered in Paris, renowned for its research, development, manufacturing, and marketing of innovative medicines and vaccines. Established in 1973, it has evolved through key mergers, including with Synthélabo in 1999 and Aventis in 2004, forming a global leader with over 90,000 employees across 90 countries. Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines, positioning it as the world's largest vaccine producer via its Sanofi Pasteur subsidiary. Its portfolio spans prescription drugs like Dupixent for eczema and autoimmune conditions, Lovenox for thrombosis, Taxotere for cancer, and treatments for rare diseases such as Gaucher's and hemophilia. Sanofi also offers over-the-counter products including Allegra and IcyHot. As an R&D-driven, AI-powered biopharma entity, it invests heavily in immunology, neurology, diabetes innovation, and mRNA technologies, maintaining a robust pipeline of 80 compounds in clinical development across five therapeutic areas to address unmet medical needs and advance public health worldwide.
In 2024, Sanofi was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Sanofi has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Sanofi are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.3 CCM/CCA - Installation, maintenance and repair of energy efficiency equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Limited Data Preview
You are viewing a limited preview of Sanofi’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories, at both aggregate and activity level, with historical coverage back to 2022.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sanofi’s data sources below and access millions more through our Disclosure Search.
a. Sanofi's ESG Report 2024
b. Sanofi's Universal Registration Document (URD) 2023
c. Sanofi's Universal Registration Document (URD) 2022
Insights into Sanofi's Revenues from Sustainable Activities
In 2024, Sanofi reported EU Taxonomy-eligible revenues of EUR 41.08 billion, representing 100% of its total turnover. Of this amount, EUR 0 of Sanofi's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into Sanofi's CAPEX from Sustainable Activities
In 2024, Sanofi reported EU Taxonomy-eligible CAPEX of EUR 5.46 billion,representing 100% of its total CAPEX. Of this amount, EUR 52.60 million of Sanofi's CAPEX was classified as EU Taxonomy-aligned, indicating that 1% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Sanofi's Taxonomy-Eligible Capex Over Time
Total Taxonomy Eligible Capex
Total Taxonomy Aligned Capex
Have Sanofi's increased its investment in sustainable activities over time?
Since 2022, Sanofi's taxonomy-aligned capital expenditure (CAPEX)decreased by 50%,indicating a long-term decline in green capital deployment, potentially signaling shifting priorities or reduced focus on sustainability-linked investments.a, c
Compared to the previous year (2023), Sanofi's taxonomy-aligned CAPEX increased by 400%,highlighting Sanofi's strengthened commitment to investing in environmentally sustainable activities or improving how such investments are classified and reported under the EU Taxonomy.a, b
How much of Sanofi's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Sanofi reported that EUR 5.46 billion of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 100% of the company's total CAPEX. Of this amount, EUR 52.60 million (1% of total CAPEX) was classified as Taxonomy-aligned. This means that 99% of Sanofi's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Sanofi's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Sanofi reported that EUR 52.60 million of its CAPEX was aligned under the EU Taxonomy, representing 1% of its total capital investment.a
This low alignment reflects that Sanofi is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Sanofi's Eligibility & Alignment Overview
Sanofi's Contribution to Environmental Objectives
Total Taxonomy Aligned Capex
How is Sanofi's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Sanofi reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 1%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Sanofi is investing in climate-related solutions?
In 2024, Sanofi allocated EUR 54.59 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 1% of the company's total capital expenditure,indicating that Sanofihas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into Sanofi's OPEX from Sustainable Activities
In 2024, Sanofi reported EU Taxonomy-eligible OPEX of EUR 5.10 billion,representing 100% of its total operating expenses (OPEX). Of this amount, EUR 0 of Sanofi's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
b
b
b
c
c
a
a